Bodey 1979
[36]
|
Cefamandole (+ carbenicillin 6 x 5 g/d)
|
FUO in neutropenic patients
|
12 g/d CI (n = 74) vs. 4 x 3 g/d II (n = 92)
|
RCT
|
Clinical cure
|
NS
|
Significant difference in clinical cure (in favor of CI) only in subpopulation with persistent neutropenia (p = 0.03)
|
*Hanes 2000
[28]
|
Ceftazidime
|
Nosocomial pneumonia in critically ill trauma patients
|
60 mg/kg/d CI (n = 17) vs. 3 x 2 g/d II (n = 15)
|
RCT
|
Length of stay Duration of leucocytosis Days to defervescence
|
NS NS NS
|
T > MIC > 90% in both II and CI groupLower antimicrobial dose in CI group
|
*Nicolau 2001
[38]
|
Ceftazidime (+tobramycin 7 mg/kg/d)
|
Nosocomial pneumonia in ICU patients
|
3 g/d CI (n = 17) vs. 3 x 2 g/d II (n = 18)
|
RCT
|
Clinical cure Microbiological cure
|
NS NS
|
Lower antimicrobial dose in CI group
|
*Lorente 2007
[52]
|
Ceftazidime (+tobramycin 7 mg/kg)
|
VAP
|
4 g/d CI (n = 56) vs. 2 x 2 g/d II (n = 65)
|
Retrospective, nonrandomized, historical chart review
|
Clinical cure
|
CI > II(p < 0.001)
| |
*Roberts 2007
[35]
|
Ceftriaxone
|
Sepsis
|
2 g/d CI (n = 29) vs. 1 x 2 g/d II (n = 28)
|
RCT
|
Clinical cure- ITT analysisa priori
|
NS CI > II (p = 0.04)
|
Significant difference in clinical cure only in an ‘a priori’ defined subgroup of patients who received at least 4 days of ceftriaxone therapy (to exclude patients that were not ill enough or too ill)
|
Van Zanten 2007
[17]
|
Cefotaxime
|
COPD exacerbations
|
2 g/d CI (n = 47) vs. 3 x 1 g/d II (n = 46)
|
RCT
|
Clinical cure
|
NS
|
Lower antimicrobial dose in CI group
|
*Georges 2005
[41]
|
Cefepime (+ amikacin 15 mg/kg/d)
|
Severe pneumonia or bacteremia
|
4 g/d CI (n = 26) vs. 2 x 2 g/d II (n = 24)
|
RCT
|
Clinical cure
|
NS
| |